primaryid int64 82.9M 2.23B | caseid int64 8.29M 23.4M | caseversion int64 1 47 | i_f_code stringclasses 2
values | event_dt float64 20M 20.2M ⌀ | mfr_dt float64 20.2M 20.2M ⌀ | init_fda_dt stringdate 2011-12-14 00:00:00 2023-12-31 00:00:00 | fda_dt stringdate 2023-01-02 00:00:00 2023-12-31 00:00:00 | rept_cod stringclasses 5
values | auth_num stringclasses 98
values | mfr_num stringlengths 13 54 ⌀ | mfr_sndr stringclasses 138
values | lit_ref stringclasses 81
values | age float64 0 24.3k ⌀ | age_cod stringclasses 4
values | age_grp stringclasses 6
values | sex stringclasses 3
values | e_sub stringclasses 2
values | wt float64 2 245 ⌀ | wt_cod stringclasses 2
values | rept_dt stringdate 2022-12-21 00:00:00 2023-12-31 00:00:00 | to_mfr stringclasses 2
values | occp_cod stringclasses 5
values | reporter_country stringclasses 48
values | occr_country stringclasses 46
values | _quarter stringclasses 4
values | age_years float64 0 95 ⌀ | sex_label stringclasses 3
values | reporter_type stringclasses 5
values | report_type stringclasses 5
values | wt_kg float64 2 175 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
233,419,091 | 23,341,909 | 1 | I | null | 20,231,221 | 2023-12-27 | 2023-12-27 | EXP | null | JP-BRISTOL-MYERS SQUIBB COMPANY-2023-187696 | BRISTOL MYERS SQUIBB | null | null | null | null | null | Y | null | null | 2023-12-27 | null | MD | JP | JP | 2023Q4 | null | Unknown | Physician | Expedited | null |
226,151,206 | 22,615,120 | 6 | F | null | 20,230,801 | 2023-06-19 | 2023-08-09 | 30DAY | null | US-PFIZER INC-PV202300105900 | PFIZER | null | 14 | YR | null | F | Y | null | null | 2023-08-09 | null | CN | US | US | 2023Q3 | 14 | Female | Consumer | 30DAY | null |
228,514,881 | 22,851,488 | 1 | I | null | 20,230,814 | 2023-08-22 | 2023-08-22 | EXP | null | CA-JNJFOC-20200405024 | JOHNSON AND JOHNSON | null | 65 | YR | E | F | Y | 79 | KG | 2023-08-23 | null | HP | CA | CA | 2023Q3 | 65 | Female | Health professional | Expedited | 79 |
231,063,011 | 23,106,301 | 1 | I | null | 20,231,024 | 2023-10-25 | 2023-10-25 | PER | null | US-AMGEN-USASP2023189083 | AMGEN | null | null | null | null | null | Y | null | null | 2023-10-25 | null | CN | US | US | 2023Q4 | null | Unknown | Consumer | Periodic | null |
220,244,991 | 22,024,499 | 1 | I | null | 20,220,310 | 2023-02-23 | 2023-02-23 | EXP | null | US-ROCHE-3049161 | ROCHE | null | null | null | null | F | Y | null | null | 2023-02-23 | null | CN | US | null | 2023Q1 | null | Female | Consumer | Expedited | null |
220,269,411 | 22,026,941 | 1 | I | null | 20,221,006 | 2023-02-23 | 2023-02-23 | EXP | null | US-ROCHE-3195973 | ROCHE | null | null | null | A | F | Y | null | null | 2023-02-23 | null | CN | US | null | 2023Q1 | null | Female | Consumer | Expedited | null |
218,702,635 | 21,870,263 | 5 | F | 20,220,101 | 20,231,023 | 2023-01-17 | 2023-11-03 | EXP | null | US-MALLINCKRODT-T202300006 | MALLINCKRODT | null | 82 | YR | E | F | Y | null | null | 2023-11-04 | null | HP | US | US | 2023Q4 | 82 | Female | Health professional | Expedited | null |
220,803,591 | 22,080,359 | 1 | I | null | 20,230,227 | 2023-03-09 | 2023-03-09 | EXP | null | CN-FERRINGPH-2023FE01027 | FERRING | Wang YN, Zheng LW, Fu LL, Xu Y, Zhang XY. Heterotopic pregnancy after assisted reproductive techniques with favorable outcome of the intrauterine pregnancy: A case report. World J Clin Cases. 2023;11 (3):669-676 | null | null | null | null | Y | null | null | 2023-03-09 | null | HP | CN | CN | 2023Q1 | null | Unknown | Health professional | Expedited | null |
223,102,811 | 22,310,281 | 1 | I | null | 20,230,508 | 2023-05-11 | 2023-05-11 | EXP | null | US-JAZZ PHARMACEUTICALS-2023-US-010268 | JAZZ | null | null | null | null | F | Y | null | null | 2023-05-11 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Expedited | null |
221,180,284 | 22,118,028 | 4 | F | 20,230,314 | 20,230,628 | 2023-03-21 | 2023-06-30 | EXP | null | IT-ROCHE-3312719 | ROCHE | null | 77 | YR | null | F | Y | null | null | 2023-06-30 | null | HP | IT | null | 2023Q2 | 77 | Female | Health professional | Expedited | null |
227,557,951 | 22,755,795 | 1 | I | null | null | 2023-07-26 | 2023-07-26 | DIR | FDA-CDER-CTU-2023-54643 | null | FDA-CTU | null | 66 | YR | null | F | N | null | null | 2023-07-26 | N | HP | US | null | 2023Q3 | 66 | Female | Health professional | Direct | null |
228,290,821 | 22,829,082 | 1 | I | null | 20,230,712 | 2023-08-16 | 2023-08-16 | PER | null | US-AURINIA PHARMACEUTICALS INC.-AUR-003849 | AURINIA PHARMACEUTICALS | null | null | null | null | M | Y | null | null | 2023-08-16 | null | CN | US | US | 2023Q3 | null | Male | Consumer | Periodic | null |
82,901,512 | 8,290,151 | 2 | F | null | 20,230,609 | 2011-12-14 | 2023-06-20 | EXP | null | IN-PFIZER INC-2011297367 | MYLAN | Bandyopadhyay D.. Celecoxib-induced fixed drug eruption. Clinical and Experimental Dermatology. 2003;28(4):452 | 57 | YR | null | F | Y | null | null | 2023-06-20 | null | HP | IN | IN | 2023Q2 | 57 | Female | Health professional | Expedited | null |
2,227,861,310 | 22,278,613 | 10 | F | 20,220,524 | 20,231,120 | 2023-05-03 | 2023-11-23 | EXP | null | CN-ASTELLAS-2023US013648 | ASTELLAS | null | 56 | YR | null | M | Y | 100.5 | KG | 2023-11-23 | null | CN | US | CN | 2023Q4 | 56 | Male | Consumer | Expedited | 100.5 |
218,619,973 | 21,861,997 | 3 | F | null | 20,230,427 | 2023-01-13 | 2023-05-04 | EXP | null | SI-SEATTLE GENETICS-2023SGN00396 | SEATTLE GENETICS | null | null | null | null | M | Y | 88 | KG | 2023-05-04 | null | MD | SI | SI | 2023Q2 | null | Male | Physician | Expedited | 88 |
220,972,941 | 22,097,294 | 1 | I | 20,220,906 | 20,230,310 | 2023-03-15 | 2023-03-15 | EXP | null | US-ABBVIE-4339793 | ABBVIE | null | 45 | YR | null | F | Y | null | null | 2023-03-15 | null | CN | US | US | 2023Q1 | 45 | Female | Consumer | Expedited | null |
214,445,614 | 21,444,561 | 4 | F | 20,220,112 | 20,230,129 | 2022-10-12 | 2023-02-09 | EXP | null | AT-JNJFOC-20220114852 | JOHNSON AND JOHNSON | null | 54 | YR | A | M | Y | 110 | KG | 2023-02-09 | null | MD | AT | AT | 2023Q1 | 54 | Male | Physician | Expedited | 110 |
223,568,012 | 22,356,801 | 2 | F | 20,190,705 | 20,230,618 | 2023-05-23 | 2023-06-20 | EXP | null | IT-BAUSCH-BL-2023-007824 | BAUSCH AND LOMB | null | 46 | YR | null | F | Y | null | null | 2023-06-20 | null | MD | IT | IT | 2023Q2 | 46 | Female | Physician | Expedited | null |
230,126,261 | 23,012,626 | 1 | I | null | 20,230,927 | 2023-09-30 | 2023-09-30 | EXP | null | US-ABBVIE-5429470 | ABBVIE | null | null | null | null | null | Y | null | null | 2023-09-30 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Expedited | null |
210,713,543 | 21,071,354 | 3 | F | 20,200,101 | 20,221,228 | 2022-07-12 | 2023-01-04 | EXP | null | US-AMERICAN REGENT INC-2022001891 | AMERICAN REGENT | null | null | null | null | F | Y | 89.161 | KG | 2023-01-04 | null | MD | US | US | 2023Q1 | null | Female | Physician | Expedited | 89.2 |
229,926,601 | 22,992,660 | 1 | I | null | 20,230,712 | 2023-09-27 | 2023-09-27 | EXP | null | US-ENDO-CASE-0019173 | ENDO | null | null | null | null | F | Y | null | null | 2023-09-27 | null | CN | US | null | 2023Q3 | null | Female | Consumer | Expedited | null |
233,123,491 | 23,312,349 | 1 | I | 20,230,101 | 20,231,214 | 2023-12-19 | 2023-12-19 | PER | null | US-BIOGEN-2023BI01199620 | BIOGEN | null | null | null | null | F | Y | null | null | 2023-12-19 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | null |
223,306,081 | 22,330,608 | 1 | I | 20,210,101 | 20,230,505 | 2023-05-17 | 2023-05-17 | EXP | null | CZ-AUROBINDO-AUR-APL-2023-036260 | AUROBINDO | Tisancinova J. Pulmonary toxicity of amiodarone anddronedarone | 67 | YR | null | M | Y | 98 | KG | 2023-05-17 | null | PH | CZ | CZ | 2023Q2 | 67 | Male | Pharmacist | Expedited | 98 |
232,419,821 | 23,241,982 | 1 | I | null | 20,231,128 | 2023-11-29 | 2023-11-29 | PER | null | NVSC2023US254081 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-11-29 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | null |
230,152,111 | 23,015,211 | 1 | I | null | null | 2023-10-02 | 2023-10-02 | DIR | FDA-CDER-CTU-2023-72252 | null | FDA-CTU | null | 72 | YR | null | F | N | null | null | 2023-10-02 | N | null | US | null | 2023Q4 | 72 | Female | null | Direct | null |
228,763,371 | 22,876,337 | 1 | I | null | 20,230,822 | 2023-08-29 | 2023-08-29 | EXP | null | US-BIOGEN-2023BI01222847 | BIOGEN | null | null | null | null | F | Y | null | null | 2023-08-29 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Expedited | null |
226,357,471 | 22,635,747 | 1 | I | null | 20,230,621 | 2023-06-23 | 2023-06-23 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-088242 | BRISTOL MYERS SQUIBB | Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, et al. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leukemia and Lymphoma. 2023 Jun 15;1-8. doi:10.1080/10428194.2023.2223740. | 77 | YR | E | M | Y | null | null | 2023-06-23 | null | HP | US | US | 2023Q2 | 77 | Male | Health professional | Periodic | null |
229,446,492 | 22,944,649 | 2 | F | 20,230,901 | 20,231,009 | 2023-09-14 | 2023-10-19 | PER | null | US-SA-2023SA276683 | SANOFI AVENTIS | null | 81 | YR | E | F | Y | null | null | 2023-10-19 | null | MD | US | US | 2023Q4 | 81 | Female | Physician | Periodic | null |
218,699,311 | 21,869,931 | 1 | I | null | 20,221,221 | 2023-01-17 | 2023-01-17 | EXP | null | US-ALKEM LABORATORIES LIMITED-US-ALKEM-2022-14436 | ALKEM | Bushara O, Miller D, Giubellino A, Schomaker M et.al.. Diagnosis of epidermodysplasia verruciformis: two cases highlighting the role of direct HPV L1 gene sequencing. J Cutan Pathol. 2019;46:436-441 | 56 | YR | null | M | Y | null | null | 2023-01-17 | null | HP | US | US | 2023Q1 | 56 | Male | Health professional | Expedited | null |
222,686,871 | 22,268,687 | 1 | I | 20,230,110 | 20,230,420 | 2023-05-01 | 2023-05-01 | EXP | FR-AFSSAPS-NY2023000502 | FR-Accord-355410 | ACCORD | null | 55 | YR | A | F | Y | null | null | 2023-04-29 | null | PH | FR | FR | 2023Q2 | 55 | Female | Pharmacist | Expedited | null |
233,337,061 | 23,333,706 | 1 | I | null | 20,231,215 | 2023-12-23 | 2023-12-23 | PER | null | US-AMGEN-USASP2023225650 | AMGEN | null | null | null | null | F | Y | null | null | 2023-12-22 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | null |
223,405,241 | 22,340,524 | 1 | I | null | 20,230,511 | 2023-05-18 | 2023-05-18 | EXP | null | CA-MYLANLABS-2023M1050187 | MYLAN | null | 61 | YR | null | F | Y | null | null | 2023-05-18 | null | CN | CA | CA | 2023Q2 | 61 | Female | Consumer | Expedited | null |
230,153,121 | 23,015,312 | 1 | I | null | 20,230,922 | 2023-10-02 | 2023-10-02 | EXP | null | CA-Covis Pharma GmbH-2021COV19117 | COVIS PHARMA | null | 41 | YR | A | F | Y | null | null | 2023-10-02 | null | CN | CA | CA | 2023Q4 | 41 | Female | Consumer | Expedited | null |
225,851,941 | 22,585,194 | 1 | I | 20,221,117 | 20,230,608 | 2023-06-09 | 2023-06-09 | EXP | null | NVSC2023PK132354 | NOVARTIS | null | 60 | YR | null | F | Y | 74 | KG | 2023-06-09 | null | CN | PK | PK | 2023Q2 | 60 | Female | Consumer | Expedited | 74 |
220,227,581 | 22,022,758 | 1 | I | 20,230,218 | 20,230,219 | 2023-02-22 | 2023-02-22 | PER | null | US-PFIZER INC-202300073897 | PFIZER | null | 80 | YR | null | F | Y | null | null | 2023-02-22 | null | CN | US | US | 2023Q1 | 80 | Female | Consumer | Periodic | null |
221,723,131 | 22,172,313 | 1 | I | 20,210,101 | 20,230,310 | 2023-04-04 | 2023-04-04 | PER | null | US-ABBVIE-4337734 | ABBVIE | null | null | null | null | M | Y | null | null | 2023-04-04 | null | CN | US | US | 2023Q2 | null | Male | Consumer | Periodic | null |
223,345,491 | 22,334,549 | 1 | I | null | 20,230,302 | 2023-05-17 | 2023-05-17 | EXP | null | US-ROCHE-3161881 | ROCHE | null | null | null | A | F | Y | null | null | 2023-05-18 | null | CN | US | null | 2023Q2 | null | Female | Consumer | Expedited | null |
226,740,112 | 22,674,011 | 2 | F | 20,230,630 | 20,230,731 | 2023-07-05 | 2023-08-02 | EXP | null | US-BAYER-2023A092874 | BAYER | null | 36 | YR | A | M | Y | null | null | 2023-08-02 | null | HP | US | US | 2023Q3 | 36 | Male | Health professional | Expedited | null |
229,727,111 | 22,972,711 | 1 | I | null | null | 2023-09-20 | 2023-09-20 | DIR | FDA-CDER-CTU-2023-69555 | null | FDA-CTU | null | 60 | YR | null | F | N | null | null | 2023-09-20 | N | null | US | null | 2023Q3 | 60 | Female | null | Direct | null |
230,007,461 | 23,000,746 | 1 | I | null | 20,230,712 | 2023-09-28 | 2023-09-28 | EXP | null | US-ENDO-CASE-0022538 | ENDO | null | null | null | null | M | Y | null | null | 2023-09-28 | null | CN | US | null | 2023Q3 | null | Male | Consumer | Expedited | null |
222,383,382 | 22,238,338 | 2 | F | null | 20,230,412 | 2023-04-21 | 2023-08-17 | EXP | null | GR-AUROBINDO-AUR-APL-2023-031472 | AUROBINDO | null | 61 | YR | null | F | Y | 83 | KG | 2023-08-17 | null | PH | CA | CA | 2023Q3 | 61 | Female | Pharmacist | Expedited | 83 |
226,242,712 | 22,624,271 | 2 | F | null | 20,230,621 | 2023-06-21 | 2023-06-26 | EXP | null | KW-ROCHE-3372406 | ROCHE | Abutiban F, Saleh K, Hayat S, Tarakmah H, Al-Herz, A and Ghanem A COVID-19 and reported mortality cases among rheumatic disease patients in Kuwait: Data from the Global Rheumatology Alliance registry. DOI: /10.1111/1756-185X.14771. International journal of rheumatic diseases 2023 Jun 07;:1-5. | 56 | YR | null | F | Y | null | null | 2023-06-26 | null | HP | KW | null | 2023Q2 | 56 | Female | Health professional | Expedited | null |
233,205,601 | 23,320,560 | 1 | I | null | 20,231,211 | 2023-12-20 | 2023-12-20 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-184600 | BRISTOL MYERS SQUIBB | null | 71 | YR | E | M | Y | null | null | 2023-12-20 | null | CN | US | US | 2023Q4 | 71 | Male | Consumer | Periodic | null |
220,954,401 | 22,095,440 | 1 | I | null | 20,230,309 | 2023-03-14 | 2023-03-14 | PER | null | US-PFIZER INC-PV202300046494 | PFIZER | null | 54 | YR | null | F | Y | null | null | 2023-03-13 | null | CN | US | US | 2023Q1 | 54 | Female | Consumer | Periodic | null |
231,611,001 | 23,161,100 | 1 | I | null | null | 2023-11-07 | 2023-11-07 | DIR | FDA-CDER-CTU-2023-82415 | null | FDA-CTU | null | 62 | YR | null | F | N | 91.17 | KG | 2023-11-07 | N | null | US | null | 2023Q4 | 62 | Female | null | Direct | 91.2 |
227,706,721 | 22,770,672 | 1 | I | null | 20,230,722 | 2023-08-01 | 2023-08-01 | EXP | null | US-APELLIS PHARMACEUTICALS-APL-2023-002747 | APELLIS PHARMACEUTICALS | null | null | null | A | F | Y | null | null | 2023-08-01 | null | MD | US | US | 2023Q3 | null | Female | Physician | Expedited | null |
2,068,307,921 | 20,683,079 | 21 | F | 20,220,106 | 20,231,025 | 2022-04-07 | 2023-10-30 | EXP | null | CN-SA-2022SA112293 | SANOFI AVENTIS | null | 68 | YR | E | F | Y | 58 | KG | 2023-10-30 | null | MD | CN | CN | 2023Q4 | 68 | Female | Physician | Expedited | 58 |
232,782,271 | 23,278,227 | 1 | I | 20,231,119 | 20,231,205 | 2023-12-08 | 2023-12-08 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-176351 | BRISTOL MYERS SQUIBB | null | 81 | YR | E | F | Y | null | null | 2023-12-08 | null | PH | US | PR | 2023Q4 | 81 | Female | Pharmacist | Expedited | null |
225,929,182 | 22,592,918 | 2 | F | 20,230,608 | 20,230,719 | 2023-06-13 | 2023-07-21 | PER | null | US-AMGEN-USASP2023099768 | AMGEN | null | null | null | null | M | Y | null | null | 2023-07-21 | null | CN | US | US | 2023Q3 | null | Male | Consumer | Periodic | null |
230,177,271 | 23,017,727 | 1 | I | null | 20,230,928 | 2023-10-03 | 2023-10-03 | PER | null | US-ELI_LILLY_AND_COMPANY-US202309016708 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-10-03 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | null |
228,201,651 | 22,820,165 | 1 | I | null | null | 2023-08-11 | 2023-08-11 | DIR | FDA-CDER-CTU-2023-58655 | null | FDA-CTU | null | null | null | null | M | N | null | null | 2023-08-11 | N | null | US | null | 2023Q3 | null | Male | null | Direct | null |
227,144,871 | 22,714,487 | 1 | I | null | 20,230,712 | 2023-07-18 | 2023-07-18 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-099021 | BRISTOL MYERS SQUIBB | Estes J, Malus M, Wilson L, Grayson PC, Maz M. A case of vexas: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome with co-existing DNA (cytosine-5)-methyltransferase 3A mutation complicated by localized skin reaction to tocilizumab and azacitidine. Cureus. 2023 Jun 03;15(6):1-7. doi:10.7759/cureus.39906... | 62 | YR | A | M | Y | null | null | 2023-07-18 | null | HP | US | US | 2023Q3 | 62 | Male | Health professional | Periodic | null |
228,854,861 | 22,885,486 | 1 | I | null | 20,230,808 | 2023-08-31 | 2023-08-31 | PER | null | CA-TOLMAR, INC.-23CA042526 | TOLMAR | null | null | null | null | M | Y | null | null | 2023-08-31 | null | CN | CA | CA | 2023Q3 | null | Male | Consumer | Periodic | null |
227,413,251 | 22,741,325 | 1 | I | null | 20,230,616 | 2023-07-24 | 2023-07-24 | PER | null | US-SUPERNUS Pharmaceuticals, Inc.-SUP202306-002405 | SUPERNUS | null | 17 | YR | null | M | Y | null | null | 2023-07-24 | null | HP | US | null | 2023Q3 | 17 | Male | Health professional | Periodic | null |
223,574,751 | 22,357,475 | 1 | I | null | 20,230,518 | 2023-05-24 | 2023-05-24 | EXP | null | US-SA-2023SA156835 | SANOFI AVENTIS | null | 72 | YR | E | F | Y | null | null | 2023-05-24 | null | CN | US | US | 2023Q2 | 72 | Female | Consumer | Expedited | null |
226,071,381 | 22,607,138 | 1 | I | 20,230,101 | 20,230,426 | 2023-06-15 | 2023-06-15 | PER | null | US-REVANCE THERAPEUTICS INC.-US-REV-2023-000189 | REVANCE THERAPEUTICS | null | null | null | null | null | Y | null | null | 2023-06-15 | null | MD | US | US | 2023Q2 | null | Unknown | Physician | Periodic | null |
221,534,372 | 22,153,437 | 2 | F | 20,230,301 | 20,230,329 | 2023-03-29 | 2023-04-03 | EXP | null | US-009507513-2303USA002561 | MERCK | null | 70 | YR | null | M | Y | 90.703 | KG | 2023-04-03 | null | MD | US | US | 2023Q2 | 70 | Male | Physician | Expedited | 90.7 |
223,019,222 | 22,301,922 | 2 | F | 20,230,503 | 20,230,529 | 2023-05-10 | 2023-05-31 | PER | null | US-AMGEN-USASP2023079167 | AMGEN | null | 65 | YR | E | M | Y | null | null | 2023-05-30 | null | CN | US | US | 2023Q2 | 65 | Male | Consumer | Periodic | null |
207,752,513 | 20,775,251 | 3 | F | null | 20,230,315 | 2022-05-02 | 2023-03-27 | EXP | null | CH-ELI_LILLY_AND_COMPANY-CH202204002818 | ELI LILLY AND CO | null | null | null | null | F | Y | 74 | KG | 2023-03-27 | null | CN | CH | CH | 2023Q1 | null | Female | Consumer | Expedited | 74 |
229,221,123 | 22,922,112 | 3 | F | null | 20,230,103 | 2023-09-08 | 2023-09-13 | PER | null | US-FARMAPROD-202301-0026 | DOMPE FARMACEUTICI | null | null | null | E | F | Y | null | null | 2023-09-12 | null | CN | US | null | 2023Q3 | null | Female | Consumer | Periodic | null |
213,049,054 | 21,304,905 | 4 | F | 20,220,829 | 20,230,111 | 2022-09-07 | 2023-01-18 | EXP | null | US-JNJFOC-20220901199 | JOHNSON AND JOHNSON | null | 57 | YR | A | F | Y | 45.4 | KG | 2023-01-18 | null | MD | US | US | 2023Q1 | 57 | Female | Physician | Expedited | 45.4 |
212,187,406 | 21,218,740 | 6 | F | null | 20,230,724 | 2022-08-16 | 2023-07-27 | EXP | null | CA-ORGANON-O2208CAN001127 | ORGANON | null | 41 | YR | null | F | Y | null | null | 2023-07-27 | null | MD | CA | CA | 2023Q3 | 41 | Female | Physician | Expedited | null |
220,476,331 | 22,047,633 | 1 | I | null | 20,230,223 | 2023-03-01 | 2023-03-01 | EXP | null | CA-APOTEX-2023AP004195 | APOTEX | null | 63 | YR | null | M | Y | null | null | 2023-03-01 | null | HP | CA | CA | 2023Q1 | 63 | Male | Health professional | Expedited | null |
231,111,801 | 23,111,180 | 1 | I | null | 20,231,012 | 2023-10-26 | 2023-10-26 | EXP | CA-MHPD-E2B_06481277 | CA-Accord-385131 | ACCORD | null | 80 | YR | E | F | Y | null | null | 2023-10-26 | null | HP | CA | CA | 2023Q4 | 80 | Female | Health professional | Expedited | null |
219,072,401 | 21,907,240 | 1 | I | null | 20,230,119 | 2023-01-25 | 2023-01-25 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-009636 | BRISTOL MYERS SQUIBB | null | 40 | YR | A | F | Y | 76.66 | KG | 2023-01-25 | null | CN | US | US | 2023Q1 | 40 | Female | Consumer | Periodic | 76.7 |
231,726,731 | 23,172,673 | 1 | I | 20,221,214 | 20,230,320 | 2023-11-10 | 2023-11-10 | EXP | FR-AFSSAPS-ST2023000345 | FR-SANDOZ INC.-NVSC2023FR064728 | SANDOZ | null | 53 | YR | null | M | Y | null | null | 2023-11-10 | null | MD | FR | FR | 2023Q4 | 53 | Male | Physician | Expedited | null |
203,813,164 | 20,381,316 | 4 | F | 20,220,926 | 20,221,025 | 2022-01-27 | 2023-01-31 | PER | null | US-AMGEN-USASP2022011747 | AMGEN | null | 49 | YR | A | F | Y | null | null | 2023-01-31 | null | HP | US | US | 2023Q1 | 49 | Female | Health professional | Periodic | null |
231,950,431 | 23,195,043 | 1 | I | 20,230,803 | 20,231,108 | 2023-11-17 | 2023-11-17 | EXP | ES-AEMPS-1446102 | ES-HETERO-AMR2023ES03175 | HETERO | null | 82 | YR | null | F | Y | null | null | 2023-11-17 | null | MD | ES | ES | 2023Q4 | 82 | Female | Physician | Expedited | null |
227,473,031 | 22,747,303 | 1 | I | 20,230,701 | 20,230,719 | 2023-07-25 | 2023-07-25 | PER | null | US-SA-2023SA225652 | SANOFI AVENTIS | null | 42 | YR | A | F | Y | null | null | 2023-07-25 | null | MD | US | US | 2023Q3 | 42 | Female | Physician | Periodic | null |
229,955,302 | 22,995,530 | 2 | F | 20,230,801 | 20,230,915 | 2023-09-27 | 2023-09-29 | EXP | null | BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-408825 | RANBAXY | null | 64 | YR | null | F | Y | 70 | KG | 2023-09-29 | null | PH | BR | BR | 2023Q3 | 64 | Female | Pharmacist | Expedited | 70 |
228,597,971 | 22,859,797 | 1 | I | 20,230,807 | 20,230,811 | 2023-08-24 | 2023-08-24 | PER | null | US-BAYER-2023A113648 | BAYER | null | 76 | YR | E | M | Y | null | null | 2023-08-24 | null | CN | US | US | 2023Q3 | 76 | Male | Consumer | Periodic | null |
223,435,581 | 22,343,558 | 1 | I | null | 20,230,516 | 2023-05-19 | 2023-05-19 | PER | null | US-GLAXOSMITHKLINE-USCH2023022836 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-05-19 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Periodic | null |
227,230,121 | 22,723,012 | 1 | I | null | 20,230,712 | 2023-07-19 | 2023-07-19 | PER | null | US-SA-2023SA217227 | SANOFI AVENTIS | null | 30 | YR | A | F | Y | null | null | 2023-07-19 | null | MD | US | US | 2023Q3 | 30 | Female | Physician | Periodic | null |
218,561,051 | 21,856,105 | 1 | I | null | 20,230,110 | 2023-01-12 | 2023-01-12 | PER | null | US-AMGEN-USASP2023003800 | AMGEN | Justice J.M.; Hess A.O.; Lobo B.C. et al.. Sinonasal IgG4-related sclerosing disease: A rare entity and challenging diagnosis. Laryngoscope Investigative Otolaryngology. 2022;7 (6):1725-1732 | 19 | YR | A | M | Y | null | null | 2023-01-12 | null | MD | US | US | 2023Q1 | 19 | Male | Physician | Periodic | null |
232,370,321 | 23,237,032 | 1 | I | null | 20,231,122 | 2023-11-28 | 2023-11-28 | EXP | null | CA-GLAXOSMITHKLINE-CACH2023AMR057617 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-11-28 | null | HP | CA | CA | 2023Q4 | null | Unknown | Health professional | Expedited | null |
223,427,771 | 22,342,777 | 1 | I | null | 20,230,510 | 2023-05-19 | 2023-05-19 | EXP | null | JP-BAXTER-2023BAX021965 | BAXTER | Shimizu A.A case of intravascular disseminated aspergillosis complicated with anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia that was difficult to differentiate from aggravated underlying diseases.The 67th Annual General Assembly and Scientific Meeting of the Japan College of 2023;:788. | 65 | YR | null | M | Y | null | null | 2023-05-19 | null | HP | JP | JP | 2023Q2 | 65 | Male | Health professional | Expedited | null |
231,039,801 | 23,103,980 | 1 | I | 20,230,817 | 20,231,019 | 2023-10-25 | 2023-10-25 | EXP | FR-AFSSAPS-DJ2023001066 | FR-MYLANLABS-2023M1110652 | MYLAN | null | 70 | YR | null | M | Y | 56 | KG | 2023-10-25 | null | MD | FR | FR | 2023Q4 | 70 | Male | Physician | Expedited | 56 |
228,389,861 | 22,838,986 | 1 | I | null | 20,230,626 | 2023-08-18 | 2023-08-18 | EXP | null | US-ENDO-CASE-0003035 | ENDO | null | null | null | null | F | Y | null | null | 2023-08-18 | null | CN | US | null | 2023Q3 | null | Female | Consumer | Expedited | null |
166,496,449 | 16,649,644 | 9 | F | 20,181,007 | 20,230,517 | 2019-07-30 | 2023-05-24 | EXP | null | JP-GILEAD-2019-0420957 | GILEAD | null | 75 | YR | E | M | Y | null | null | 2023-05-24 | null | MD | JP | JP | 2023Q2 | 75 | Male | Physician | Expedited | null |
221,055,871 | 22,105,587 | 1 | I | 20,230,202 | 20,230,313 | 2023-03-17 | 2023-03-17 | EXP | ES-AEMPS-1338421 | ES-009507513-2303ESP004226 | MERCK | null | 65 | YR | null | M | Y | null | null | 2023-03-17 | null | PH | ES | ES | 2023Q1 | 65 | Male | Pharmacist | Expedited | null |
218,815,362 | 21,881,536 | 2 | F | 20,230,105 | 20,230,203 | 2023-01-19 | 2023-03-02 | PER | null | FR-TOLMAR, INC.-23FR038310 | TOLMAR | null | 77 | YR | null | M | Y | null | null | 2023-03-02 | null | PH | FR | FR | 2023Q1 | 77 | Male | Pharmacist | Periodic | null |
220,763,491 | 22,076,349 | 1 | I | 20,230,218 | 20,230,227 | 2023-03-09 | 2023-03-09 | EXP | null | JP-NOVOPROD-1029430 | NOVO NORDISK | null | null | null | null | M | Y | 69 | KG | 2023-03-09 | null | MD | JP | JP | 2023Q1 | null | Male | Physician | Expedited | 69 |
221,475,651 | 22,147,565 | 1 | I | 20,230,301 | 20,230,325 | 2023-03-28 | 2023-03-28 | PER | null | US-PFIZER INC-202300131141 | PFIZER | null | 75 | YR | null | M | Y | 87.54 | KG | 2023-03-28 | null | CN | US | US | 2023Q1 | 75 | Male | Consumer | Periodic | 87.5 |
209,532,412 | 20,953,241 | 2 | F | null | 20,230,821 | 2022-06-13 | 2023-08-22 | EXP | null | NVSC2022US135080 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-08-22 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Expedited | null |
209,777,225 | 20,977,722 | 5 | F | 20,031,111 | 20,231,215 | 2022-06-18 | 2023-12-22 | EXP | null | US-JNJFOC-20220625991 | JOHNSON AND JOHNSON | null | 60 | YR | A | F | Y | null | null | 2023-12-22 | null | LW | US | US | 2023Q4 | 60 | Female | Lawyer | Expedited | null |
221,063,742 | 22,106,374 | 2 | F | 20,230,401 | 20,230,425 | 2023-03-17 | 2023-05-02 | PER | null | US-SA-2023SA079531 | SANOFI AVENTIS | null | 11 | YR | C | F | Y | null | null | 2023-05-02 | null | HP | US | US | 2023Q2 | 11 | Female | Health professional | Periodic | null |
222,199,781 | 22,219,978 | 1 | I | null | null | 2023-04-14 | 2023-04-14 | DIR | FDA-CDER-CTU-2023-27986 | null | FDA-CTU | null | null | null | null | null | N | null | null | 2023-04-14 | N | CN | US | null | 2023Q2 | null | Unknown | Consumer | Direct | null |
218,420,661 | 21,842,066 | 1 | I | null | 20,230,107 | 2023-01-10 | 2023-01-10 | PER | null | US-JNJFOC-20230115613 | JOHNSON AND JOHNSON | null | null | null | null | F | Y | null | null | 2023-01-10 | null | HP | US | US | 2023Q1 | null | Female | Health professional | Periodic | null |
208,623,984 | 20,862,398 | 4 | F | null | 20,230,830 | 2022-05-23 | 2023-09-07 | PER | null | US-PFIZER INC-202200744135 | PFIZER | null | 77 | YR | null | M | Y | null | null | 2023-09-07 | null | CN | US | US | 2023Q3 | 77 | Male | Consumer | Periodic | null |
221,617,831 | 22,161,783 | 1 | I | null | 20,230,330 | 2023-03-31 | 2023-03-31 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-046368 | BRISTOL MYERS SQUIBB | null | 68 | YR | E | F | Y | null | null | 2023-03-31 | null | CN | US | US | 2023Q1 | 68 | Female | Consumer | Periodic | null |
192,548,922 | 19,254,892 | 2 | F | null | 20,201,221 | 2021-05-13 | 2023-06-01 | PER | null | US-UCBSA-2020054338 | UCB | null | null | null | null | F | Y | null | null | 2023-06-01 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
219,323,351 | 21,932,335 | 1 | I | 20,221,122 | null | 2023-01-31 | 2023-01-31 | DIR | 646617 | null | FDA-CTU | null | 67 | YR | null | M | N | 94.8 | KG | 2023-01-31 | N | PH | US | null | 2023Q1 | 67 | Male | Pharmacist | Direct | 94.8 |
219,250,601 | 21,925,060 | 1 | I | null | 20,230,125 | 2023-01-30 | 2023-01-30 | EXP | null | US-AstraZeneca-2023A022748 | ASTRAZENECA | null | null | null | null | M | Y | null | null | 2023-01-30 | null | MD | US | null | 2023Q1 | null | Male | Physician | Expedited | null |
226,752,391 | 22,675,239 | 1 | I | null | 20,230,623 | 2023-07-06 | 2023-07-06 | EXP | null | PT-AUROBINDO-AUR-APL-2023-045490 | AUROBINDO | Cabral SM, Ferreira P. Azacytidine-induced pneumonitis in acute myeloid leukaemia. Pulmonology. 2023;29(2):165-166 | 56 | YR | null | M | Y | null | null | 2023-07-06 | null | MD | PT | PT | 2023Q3 | 56 | Male | Physician | Expedited | null |
227,753,781 | 22,775,378 | 1 | I | 20,230,101 | 20,230,728 | 2023-08-02 | 2023-08-02 | PER | null | US-AMGEN-USASP2023133524 | AMGEN | null | 41 | YR | A | M | Y | null | null | 2023-08-02 | null | HP | US | US | 2023Q3 | 41 | Male | Health professional | Periodic | null |
233,460,231 | 23,346,023 | 1 | I | 20,231,219 | 20,231,220 | 2023-12-28 | 2023-12-28 | EXP | null | US-ABBVIE-5562415 | ABBVIE | null | 51 | YR | null | F | Y | null | null | 2023-12-28 | null | HP | US | US | 2023Q4 | 51 | Female | Health professional | Expedited | null |
219,631,961 | 21,963,196 | 1 | I | 20,230,124 | null | 2023-02-05 | 2023-02-05 | DIR | 647183 | null | FDA-CTU | null | 41 | YR | null | F | N | 61.65 | KG | 2023-02-05 | N | CN | US | null | 2023Q1 | 41 | Female | Consumer | Direct | 61.6 |
223,114,093 | 22,311,409 | 3 | F | null | 20,230,707 | 2023-05-11 | 2023-07-18 | PER | null | US-SA-2023SA145940 | SANOFI AVENTIS | null | null | null | C | M | Y | 11.7 | KG | 2023-07-18 | null | MD | US | US | 2023Q3 | null | Male | Physician | Periodic | 11.7 |
218,809,601 | 21,880,960 | 1 | I | null | 20,230,112 | 2023-01-18 | 2023-01-18 | EXP | null | AU-INCYTE CORPORATION-2023IN000380 | INCYTE | null | null | null | null | null | Y | null | null | 2023-01-19 | null | PH | AU | AU | 2023Q1 | null | Unknown | Pharmacist | Expedited | null |
226,439,952 | 22,643,995 | 2 | F | null | 20,230,717 | 2023-06-27 | 2023-07-20 | EXP | null | CA-JNJFOC-20230653316 | JOHNSON AND JOHNSON | null | 19 | YR | A | M | Y | null | null | 2023-07-20 | null | HP | CA | CA | 2023Q3 | 19 | Male | Health professional | Expedited | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.